NHS Framework - Blood Disorders including Haemophilia A and B - July 2024

A Contract Award Notice
by NHS ENGLAND

Source
Find a Tender
Type
Framework (Supply)
Duration
34 month (est.)
Value
£1
Sector
HEALTH
Published
11 Jun 2024
Delivery
01 Jul 2024 to 30 Apr 2027 (est.)
Deadline
n/a

Concepts

Location

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

Geochart for 2 buyers and 33 suppliers

2 buyers

10 suppliers

Description

Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024Offer reference number: CM/PHS/22/5661Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months.Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

Lot Division

1 CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIII

Standard Half-life Recombinant Factor VIII

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
2 CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII

CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0
3 CM/PHS/22/5661/03 Emicizumab

CM/PHS/22/5661/03 Emicizumab

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
4 CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL)

CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL)

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0
5 CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL)

CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL)

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
6 CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL)

CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL)

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0
7 CM/PHS/22/5661/07 rFIX - Standard Half Life

CM/PHS/22/5661/07 rFIX - Standard Half Life

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
8 CM/PHS/22/5661/08 Recombinant Factor VII

CM/PHS/22/5661/08 Recombinant Factor VII

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0
9 CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa

CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0
10 CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction

CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
11 CM/PHS/22/5661/11 Factor IX - High Purity Factor IX

CM/PHS/22/5661/11 Factor IX - High Purity Factor IX

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
12 CM/PHS/22/5661/12 Factor X

CM/PHS/22/5661/12 Factor X

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0
13 CM/PHS/22/5661/13 Factor XIII - Plasma Derived

CM/PHS/22/5661/13 Factor XIII - Plasma Derived

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
14 CM/PHS/22/5661/14 Factor XIII - Recombinant

CM/PHS/22/5661/14 Factor XIII - Recombinant

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0
15 CM/PHS/22/5661/15 Von willebrands factor / Factor VIII

CM/PHS/22/5661/15 Von willebrands factor / Factor VIII

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0
16 CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived

CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
17 CM/PHS/22/5661/17 Von willebrands factor - Recombinant

CM/PHS/22/5661/17 Von willebrands factor - Recombinant

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
18 CM/PHS/22/5661/18 Fibrinogen Concentrate

CM/PHS/22/5661/18 Fibrinogen Concentrate

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0
19 CM/PHS/22/5661/19 Prothrombin Complex dried

CM/PHS/22/5661/19 Prothrombin Complex dried

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
20 CM/PHS/22/5661/20 Protein C Concentrate

CM/PHS/22/5661/20 Protein C Concentrate

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0
21 CM/PHS/22/5661/21 Fresh Frozen Plasma (all blood groups)

CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups)

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
22 CM/PHS/22/5661/22 Freeze Dried Plasma

CM/PHS/22/5661/22 Freeze Dried Plasma

Award Criteria
Ease of Use 10.0
Security of Supply 15.0
PRICE 75.0
23 CM/PHS/22/5661/23 Caplacizumab

CM/PHS/22/5661/23 Caplacizumab

Award Criteria
Security of Supply 15.0
Ease of Use 10.0
PRICE 75.0

Award Detail

1 Pfizer (Surrey)
  • Standard Half-life Recombinant Factor VIII
  • Num offers: 3
  • Value: £1
2 Takeda (London)
  • Standard Half-life Recombinant Factor VIII
  • Num offers: 3
  • Value: £1
3 Octapharma (Manchester)
  • Standard Half-life Recombinant Factor VIII
  • Num offers: 3
  • Value: £1
4 Novo Nordisk (None)
  • Enhanced Half-life Recombinant Factor VIII
  • Num offers: 2
  • Value: £1
5 Sobi Swedish Orphan Biovitrum (Cambridgeshire)
  • Enhanced Half-life Recombinant Factor VIII
  • Num offers: 2
  • Value: £1
  • Contractor is an SME.
6 Roche Products (Welwyn Garden City)
  • Emicizumab
  • Num offers: 1
  • Value: £1
7 Sobi Swedish Orphan Biovitrum (Cambridgeshire)
  • Eftrenonacog alfa (rFIX EHL)
  • Num offers: 1
  • Value: £1
  • Contractor is an SME.
8 CSL Behring (West Sussex)
  • albutrepenonacog alfa (rFIX EHL)
  • Num offers: 1
  • Value: £1
9 Novo Nordisk (None)
  • nonacog beta pegol (rFIX EHL)
  • Num offers: 1
  • Value: £1
10 Pfizer (Surrey)
  • rFIX - Standard Half Life
  • Num offers: 2
  • Value: £1
11 Takeda (London)
  • rFIX - Standard Half Life
  • Num offers: 2
  • Value: £1
12 Novo Nordisk (None)
  • Recombinant Factor VII
  • Num offers: 2
  • Value: £1
13 LFB (Hertfordshire)
  • Recombinant Factor VII
  • Num offers: 2
  • Value: £1
14 Takeda (London)
  • Porcine Factor VIII - susoctocog alfa
  • Num offers: 1
  • Value: £1
15 Takeda (London)
  • Factor VIII Inhibitor Bypassing Fraction
  • Num offers: 1
  • Value: £1
16 Bio Products Laboratory (Hertfordshire)
  • Factor IX - High Purity Factor IX
  • Num offers: 1
  • Value: £1
17 Bio Products Laboratory (Hertfordshire)
  • Factor X
  • Num offers: 1
  • Value: £1
18 CSL Behring (West Sussex)
  • Factor XIII - Plasma Derived
  • Num offers: 1
  • Value: £1
19 Novo Nordisk (None)
  • Factor XIII - Recombinant
  • Num offers: 1
  • Value: £1
20 Octapharma (Manchester)
  • Von willebrands factor / Factor VIII
  • Num offers: 2
  • Value: £1
21 CSL Behring (West Sussex)
  • Von willebrands factor / Factor VIII
  • Num offers: 2
  • Value: £1
22 LFB (Hertfordshire)
  • Von willebrands factor - Plasma Derived
  • Num offers: 1
  • Value: £1
23 Takeda (London)
  • Von willebrands factor - Recombinant
  • Num offers: 1
  • Value: £1
24 LFB (Hertfordshire)
  • Fibrinogen Concentrate
  • Num offers: 3
  • Value: £1
25 Octapharma (Manchester)
  • Fibrinogen Concentrate
  • Num offers: 3
  • Value: £1
26 CSL Behring (West Sussex)
  • Fibrinogen Concentrate
  • Num offers: 3
  • Value: £1
27 Takeda (London)
  • Prothrombin Complex dried
  • Num offers: 3
  • Value: £1
28 Octapharma (Manchester)
  • Prothrombin Complex dried
  • Num offers: 3
  • Value: £1
29 CSL Behring (West Sussex)
  • Prothrombin Complex dried
  • Num offers: 3
  • Value: £1
30 Takeda (London)
  • Protein C Concentrate
  • Num offers: 1
  • Value: £1
31 Octapharma (Manchester)
  • Fresh Frozen Plasma (all blood groups)
  • Num offers: 1
  • Value: £1
32 Unnamed (None)
  • Freeze Dried Plasma
  • CONTRACT NOT AWARDED – NO SUCCESSFUL BIDDERS.
33 Unnamed (None)
  • Caplacizumab
  • CONTRACT NOT AWARDED – NO SUCCESSFUL BIDDERS.

Renewal Options

Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Options are available.
  • Award on basis of price.

Other Information

This award notice and related ITO documentation was initially advertised under the tender reference CM/PHS/22/5561, however this was a typo. Award documentation and subsequent notices reflect the correct tender reference of CM/PHS/22/5661.

Reference

Domains